Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

Epeius

Financiado

Redesigning aortic endograft: enabling in-situ personalized aneurysm healing

Forty years ago, the endograft (EG) enabled the endovascular treatment of aortic aneurysm (AoA) and revolutionized vascular surgery. Still, since then, its technological concept has remained substantially unchanged: EG is a passiv... ver más

30/09/2029

UNIPV

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

UNIVERSITA DEGLI STUDI DI PAVIA No se ha especificado una descripción o un objeto social para esta compañía.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-03-14

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

ERC-2023-COG: ERC CONSOLIDATOR GRANTS

I+D

Cerrada hace 1 año

0% 100% 100%

1 Participantes

UNIPV

1.99M€ | Lider

Proyectos interesantes

REBORN Full human based multi scale constructs with jammed regenera... 2M€ Cerrado

MAT2015-65601-R NUEVAS ESTRATEGIAS DE BIOIMPRESION PARA REGENERACION OSEA Y... 339K€ Cerrado

PTQ-10-02483 Nuevos dispositivos y procesos en Biomateriales para Ingenie... 68K€ Cerrado

VascArbor Vascular Tree Formation in Multi Structural Tissue Engineeri... 2M€ Cerrado

THOR building vascular networks and Blood-Brain-Barriers through... 3M€ Cerrado

PersonalBone Multifunctional Personalized Self Assembled Biomaterials for... 1M€ Cerrado

Últimas noticias

01-12-2024: REDES En las últimas 48 horas el Organismo REDES ha otorgado 1337 concesiones

01-12-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

01-12-2024: AEI En las últimas 48 horas el Organismo AEI ha otorgado 23 concesiones

Duración del proyecto: 66 meses Fecha Inicio: 2024-03-14
Fecha Fin: 2029-09-30

Presupuesto del proyecto 2M€

Descripción del proyecto Forty years ago, the endograft (EG) enabled the endovascular treatment of aortic aneurysm (AoA) and revolutionized vascular surgery. Still, since then, its technological concept has remained substantially unchanged: EG is a passive device aimed at treating the AoA in its late stage, not to cure the disease, even when discovered early. This proposal introduces a bio-engineered process to redesign EGs as 3D bio-printed, bioresorbable devices loaded with active drug components and validated in-vitro to enable the paradigm shift: from end-stage treatment to early personalized healing. To this aim, EPEIUS must tackle three open challenges: 1) available (animal) models often fail to predict human safety and efficacy for candidate therapies; 2) potentially effective drugs are challenging to deliver in therapeutic concentrations at the target; 3) consequently, there is a limited capacity of AoA healing even for compounds that were preclinically promising. We hypothesize that these challenges can be solved simultaneously by designing and fabricating a human in-vitro model of AoA where we can track AoA progression in the presence/absence of bioengineered EG, delivering therapeutic drugs. Grounded on a multi-disciplinary approach, EPEIUS will act as the trojan horse to enable the local healing of arterial walls. To verify our hypothesis, we will integrate 3D bioprinting and computational biomechanics to: Aim 1. Create an in-vitro model of AoA recapitulating dysfunction of endothelial and vascular smooth muscle cells, degeneration of extra-cellular matrix, overall driven by inflammatory state. Aims 2. Create a customizable EG to carry drug in-situ. Aims 3. Assess in-vitro the regenerative power of the mesenchymal stem cells’ secretome to heal AoA. EPEIUS will directly tackle a prominent medical issue but we are convinced that this innovation in computer-aided engineering, additive manufacturing, and in-vitro pharmacology will create the next generation endovascular device.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores